Results 181 to 190 of about 78,184 (307)

BTK Inhibitor [PDF]

, 2020
openaire   +1 more source

The Multifaceted Legacy of Thalidomide: Chemistry and Biology Driving Modern Drug Design

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
Thalidomide serves as a molecular nexus linking chemistry and biology: advances in synthesis and structural understanding enable protein degradation technologies, while its immunomodulatory activity underpins anti‐inflammatory and anticancer therapies.
Konstantina Nikovia, Michael Kapsalis, Michael Georgoulakis, Athanasios Panousis, Constantinos G. Neochoritis   +4 more
wiley   +1 more source

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

Cancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi, Zijian Zhang, Yang Yang, Haichuan Zhu   +3 more
wiley   +1 more source

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

New England Journal of Medicine, 2013
J. Byrd, R. Furman, S. Coutre, I. Flinn, J. Burger, K. Blum, B. Grant, J. Sharman, M. Coleman, W. Wierda, Jeffrey A Jones, Weiqiang Zhao, N. Heerema, A. Johnson, J. Sukbuntherng, B. Chang, F. Clow, E. Hedrick, J. Buggy, D. James, S. O'brien   +20 more
semanticscholar   +1 more source

Nationwide Incidence, Treatment Pattern, and Prognosis of Primary CNS Lymphoma in Taiwan, 2012–2020: A Retrospective Cohort Study

Cancer Medicine, Volume 15, Issue 4, April 2026.
Using data from the Taiwan Cancer Registry, the Taiwan National Health Insurance Research Database, and the Taiwan National Death Registry, this nationwide real‐world study examined the epidemiology, treatment patterns, prognosis, medical costs, and adverse events associated with primary central nervous system lymphoma (PCNSL) in Taiwan over a nine ...
Fei‐Yuan Hsiao, Hung‐Yu Lin, Ho‐Min Chen, Wan‐Hsuan Hsu, Bor‐Sheng Ko   +4 more
wiley   +1 more source

Epigenetic Compound Library Screen Identifies Ibrutinib as an Inhibitor of Ovarian Clear Cell Carcinoma Viability

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Background Ovarian clear cell carcinoma (OCCC) is an endometriosis‐associated ovarian cancer subtype. Somatic mutations in OCCC are reported in ARID1A, PIK3CA, and the TERT promoter (TERTp), as well as less commonly in KRAS and TP53 among other genes. OCCC is typically resistant to standard‐of‐care chemotherapy, especially after relapse. While
Yue Ma, Kristie‐Ann Dickson, Farhana A. Sarker, Amani Alghalayini, Natisha R. Field, Tao Xie, Tali S. Skipper, Anastasia Karafotias, Sarina Briscas, Christine Yee, Caroline E. Ford, Nikola A. Bowden, Nham Tran, Deborah J. Marsh   +13 more
wiley   +1 more source

Comparative Outcomes of Consolidation Strategies After R‐MVP Induction in Primary Diffuse Large B‐Cell Lymphoma of the Central Nervous System

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Background The optimal consolidation strategy following high‐dose methotrexate (MTX)–based induction in primary central nervous system lymphoma (PCNSL) remains controversial. This study compared real‐world outcomes of different consolidation modalities in patients responsive to rituximab, MTX, vincristine, and procarbazine (R‐MVP) induction ...
Sang‐A Kim, Jung Sun Kim, Ji Yun Lee, Joo Ho Lee, Keun‐Yong Eom, Chul‐Kee Park, Chae‐Yong Kim, Dae Seog Heo, Jeong‐Ok Lee, Tae Min Kim   +9 more
wiley   +1 more source

Life‐Threatening Acute Tumor Lysis Syndrome With Multiorgan Failure Following First Cycle of Bendamustine–Rituximab in Chronic Lymphocytic Leukemia: A Case Report and Brief Review

Clinical Case Reports, Volume 14, Issue 4, April 2026.
Graphical timeline of the patient’s clinical course. The timeline illustrates key events in a patient with CLL who developed acute tumor lysis syndrome after the first cycle of bendamustine–rituximab, including TLS onset, multiorgan failure, hemodialysis, and full recovery. ABSTRACT Chronic lymphocytic leukemia is not uniformly low risk for tumor lysis
Malegna Temesgen Garuma, Kebede H. Begna, Tesfaye Belete Amare, Mengisteab Kassahun Desta, Derebe Shashigo Leilago, Humud Mohammed Ahmed   +5 more
wiley   +1 more source

Evolution of Drug Development Trends in Multiple Sclerosis: Analysis of Mainland China and Global Landscapes From 2004 to 2024

CNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.
This registry‐based analysis of 1183 MS clinical trials (2004–2024) shows sustained global activity and a marked increase in mainland China after 2018, predominantly driven by late‐phase and bioequivalence studies. Trial density varied across regions, and IFNAR, CD20, and S1PR1 were the most frequently investigated targets. ABSTRACT Background Multiple
Chaoyang Chen, Zhenyu Niu, Ting Yang, Xuanling Zhang, Ran Wei, Xiaocong Pang, Ran Liu, Ying Zhou   +7 more
wiley   +1 more source

Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK

Science Signaling, 2022
K. Dhami, Anirban Chakraborty, T. Gururaja, L. Cheung, Chaohong Sun, F. Deanda, Xiaodong Huang   +6 more
semanticscholar   +1 more source